KDR and neoplasm: In mice bearing subcutaneously injected B16 melanomas, anti-VEGFR-2 CAR-T cells did not enhance the antitumour affect alone but in combination with CARs targeted against melanoma; they worked synergistically to increase intra-tumoural T cells, eradicating B16 tumours and extending progression free survival [4,175,179].